Medtronic: "No delay" to CoreValve's US approval despite trial redesign
This article was originally published in Clinica
Executive Summary
US approval of Medtronic's CoreValve transcatheter aortic heart valve is still expected in 2014, the company has confirmed. Medtronic is to modify its pivotal US trial of the valve, but the firm told Clinica that this would not delay the valve's passage to US approval.